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Abstract 
Title: Occult microscopic endometriosis: an undetectable finding by laparoscopy in 
normal peritoneum 
Study question: Are there any occurrence and activity of hidden (occult) endometriotic 
lesions, an undetectable finding by naked eyes, in normal peritoneum of women with and 
without visible endometriosis?  
Summary answer: We detected higher occurrence of occult microscopic endometriosis 
(OME) in normal peritoneum of women with visible endometriosis than in control 
women and confirmed that these OME lesions have variable amount of tissue activity as 
measured by proliferative potentiality of these lesions.  
What is known already: Using small number of cases, the concept of invisible 
microscopic endometriosis or OME in visually normal peritoneum has been reported in 
more than a decade ago with a controversial opinion regarding their tissue activity and 
clinical significance.    
Study design, size and duration: Case-controlled biological research using 
prospectively collected normal peritoneal samples from women with and without visible 
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endometriosis and their retrospective evaluation.   
Participants/materials, setting, methods: Normal peritoneal biopsy specimens from 
different anatomical sites of pelvis were collected from 151 women with endometriosis 
and 62 control women during laparoscopy. A histological search of all peritoneal biopsy 
specimens for the detection of invisible endometriosis was done and confirmed by 
immunoreaction to Ber-EP4 (epithelial cell marker), CD10 (stromal cell marker), and 
Calretinin (mesothelial cell marker). Tissue expressions of estrogen/progesterone 
receptors (ER/PR) and cell proliferation marker, Ki-67 were performed by 
immunohistochemistry to identify tissue activity.   
 Main results and the role of chance: Three different patterns of OME were detected 
based on (I) presence of typical gland/stroma, (II) reactive hyperplastic change of 
endometrioid epithelial cells with surrounding stroma, and (III) single-layered 
epithelium-lined cystic lesions with surrounding stroma. A higher tendency in the 
occurrence of OME was found in women with visible endometriosis (15.2%, 23/151) 
comparing to control women (6.4%, 4/62) (p=0.06, X2 test). The epithelial cells and/or 
stromal cells of OME lesions were immunoreactive to Ber-EP4/CD10 but non-reactive to 
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Calretinin. ER and PR expression was observed in all patterns OME lesions. Ki-67 index 
was significantly higher in pattern I/II OME lesions than in pattern III OME lesions 
(p<0.05 for each). We re-confirmed a decade long old concept of invisible (occult) 
endometriosis in visually normal peritoneum of women with visible endometriosis and 
found that a proportion of these occult peritoneal lesions displayed increased tissue 
activity. 
Limitations, reasons for cautions: Bias in the incidence rate of OME lesions in this 
study cannot be ignored, because we could not analyze biopsy specimens from the Pouch 
of Douglas of women with r-ASRM stage III-IV endometriosis due to the presence of 
variable amount of adhesion in the pelvis. 
Wider implications of the findings: Our time-consuming current findings indicate the 
acceptability of OME lesions in normal peritoneum even it is undetected by laparoscopy. 
The existence of a variable amount of tissue activity in these occult lesions may 
contribute to the recurrence/occurrence of endometriosis or persistence/recurrence of 
pain manifestation in women even after successful ablation or excision of visible lesions 
by laparoscopy.   
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Introduction 
Endometriosis is an estrogen-dependent chronic inflammatory disease mostly 
affecting women of reproductive age. Originally described over three hundred years ago, 
endometriosis is classically defined by the presence of endometrial glands and stroma in 
extrauterine locations (Burney and Giudice, 2012). There are some established 
hypotheses and regulatory factors supporting the development or maintenance of 
endometriosis (Burney and Giudice, 2012; Attar and Bulun, 2006). Recently it has been 
demonstrated that besides hormonal regulation, both secondary and initial inflammatory 
mediators are known to involve in the growth of endometriosis (Khan et al., 2008, 2009, 
2010a). However, it is difficult to uniformly explain the pathogenesis of endometriosis by 
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a single factor. Even after long three hundred years, most of the literatures still claim that 
exact pathogenesis of endometriosis is unclear and stamp endometriosis as an enigmatic 
disease. Recurrence of pain and lesion is still occurring after effective medical or surgical 
therapies.  
The detection and visible diagnosis of peritoneal endometriosis is usually 
performed by laparoscopy, a gold standard modality and is microscopically confirmed by 
histopathology. Even with the careful eyes of expert surgeons, there is obvious chance to 
miss or overlook hidden (occult) lesions in visually normal peritoneum. Therefore, 
immense interest could arise to randomly collect visually normal peritoneum from 
different anatomical location in pelvis and to investigate the nature of these visually 
undetectable lesions of endometriosis. The concept of microscopic endometriosis in 
visually normal peritoneum was first reported by Murphy (1986) and subsequently 
confirmed with an incidence rate of 6-13% (Nisolle et al., 1990, Balasch et al., 1996). 
With the elapse of more than one decade, further information on invisible or occult 
microscopic endometriosis (IME or OME) is lacking.  
Therefore, we histologically examined all biopsy specimens derived from the 
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visually normal peritoneum of women with and without endometriosis to detect the 
possible occurrence of OME. The question still remains, if hidden endometriosis lesions 
could be detected in normal peritoneum, are these invisible lesions really inactive as 
proposed in a previous report? (Donnez and Langrndonckt, 2004) or they truly retain 
some tissue activity. If tissue activity of OME is there, this could be a clinically important 
issue. To address this question, we investigated the expression patterns of some tissue 
activity markers including ovarian steroid receptors and cell proliferation marker in 
histologically confirmed OME lesions. With the belief in mind that all cells of epithelial 
origin are embryologically derived from coelomic epithelium, we further extended our 
experiment to examine the immunoreaction of CA125/MUC16, a marker of cells derived 
from coelomic epithelium and its derivatives, in visible peritoneal lesions and in OME 
lesions. Finally we discussed the possible origin of OME, so called IME.     
Materials and Methods 
Subjects.  During the period between January 2005 and June 2010, peritoneal 
biopsy samples from different anatomical locations in pelvis were randomly and 
prospectively collected from women with and without visible endometriosis during 
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laparoscopy (Stortz, Germany). With the concept of occult endometriosis in mind, we 
collected peritoneal biopsy samples together with visible peritoneal lesions. During this 
study period, we were able to collect a total of 895 peritoneal biopsy samples from 387 
women with and without endometriosis. 
The anatomical location in pelvis and quality of each collected peritoneal 
biopsy specimens were retrospectively reviewed and confirmed by video image and 
tissue observation (KNK, AF, MK). Visually normal peritoneum was examined from a 
distance of 3-4cm and an effort was made to select normal peritoneum based on the 
following criteria: (i) smooth peritoneal surface with no text irregularity, (ii) no abnormal 
vascular pattern, (iii) transparent peritoneum, (iv) no sub-peritoneal cystic structures, and 
(v) no superficial fibrosis. A sample of visually normal peritoneum is shown in Figure 1. 
We used our laparoscopic technique where the laparoscope was 3-4cm away from the 
peritoneal surface and is almost similar to the technique described by Nisolle et al. (1990). 
After careful observation and analysis, we could finally sorted out 227 visually normal 
peritoneal samples from 151 women with visible endometriosis and 78 samples from 62 
women without any visible peritoneal lesions (control). We did not analyze remaining 
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peritoneal samples from the rest of 174 women, because these samples did not satisfy the 
criteria of normal peritoneum.   
Women with visible endometriosis aged between 23 and 50 years were 
recruited by either elective laparoscopy for infertility or diagnostic laparoscopy for 
dysmenorrhea and subsequently confirmed by histology. The control group, between 19 
and 48 years old, consisted of fertile women without any evidence of visible 
endometriosis and were operated on for benign ovarian cysts (dermoid cyst/serous cyst 
adenoma/mucinous cyst adenoma). The staging and the morphological distribution of 
peritoneal lesions were based on the revised classification of the American Society of 
Reproductive Medicine (r-ASRM) (1997). All control women and women with 
endometriosis had regular menstrual cycles (28-35 days) except cases with hormonal 
therapy. The phases of the menstrual cycle was determined by histological dating of 
eutopic endometrial samples taken simultaneously with pathological lesions during 
laparoscopy.  
The distribution of biopsy specimens from visually normal peritoneum based 
on anatomical location in pelvis is as follows: visible endometriosis (n=227), Pouch of 
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Douglas (n=87), uterovesicle space (n=104), right sacrouterine ligament (n=20), left 
sacrouterine ligament (n=16); control women (n=78), Pouch of Douglas (n=32), 
uterovesicle space (n=35), right sacrouterine ligament (n=6), left sacrouterine ligament 
(n=5). We could not collect biopsy specimens from the Pouch of Douglas in women with 
r-ASRM stage III-IV endometriosis due to the presence of adhesion. Instead, we collected 
peritoneal biopsy specimens from other anatomical locations in these women. After 
holding up peritoneum with forceps, all peritoneal biopsy samples were collected from 
respective sites by cutting with scissor 1cm in depth and with a length of 1.0 to 2.5 cm. In 
our initial trial, we could not collect enough connective tissue just by punch biopsy from 
any of these anatomical sites.   
All biopsy specimens were collected in accordance with the guidelines of the 
Declaration of Helsinki and were approved by the Institutional Review Board of 
Nagasaki University. An informed consent was obtained from all women.  
Antibodies used. We performed immunohistochemical studies to investigate 
immunoreaction of target antigen in the serial section of biopsies using following 
antibodies: Ber-EP4 (epithelial cell marker, 1:200), M0804, mouse monoclonal, Dako, 
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Denmark; CD10 (stromal cell marker, 1:40), 56C6, mouse monoclonal, Dako, Denmark; 
Calretinin (mesothelial cell marker, 1:50), SP13, rabbit monoclonal, Nichirei Bioscience, 
Japan; ER (estrogen receptor, 1:50), ER1D5, mouse monoclonal, Dako, Denmark; PR 
(progesterone receptor, 1:40), NCL-PGR, mouse monoclonal, Dako, Denmark; 
aromatase cytochrome P450 (estrogen metabolizing enzyme, 1:100), ab18995, rabbit 
polyclonal, abcam, Japan; Ki-67 (cell proliferation marker, 1:100), MIB-1, mouse 
monoclonal, Immunotech, Marseille, France; Toll-like receptor 4 (TLR4, a pattern 
recognition receptor, 1:50), ab22048, mouse monoclonal, abcam, Japan; D2-40 
(lymphatic vessel marker, 1:100), M3619, mouse monoclonal, Dako, Denmark; von 
Willebrand factor (VWF, micro-vessel marker, 1:25), F8/86, M0616, mouse monoclonal, 
Dako, Denmark; CA125/MUC16 (marker of cells derived from coelomic epithelium, 
1:20), M11, mouse monoclonal, Dako, Denmark. Non-immune mouse immunoglobulin 
(Ig) G1 antibody (1:50, Dako)) was used as a negative control.  
In an attempt to detect hidden lesions of endometriosis, all slides of biopsy 
specimens derived from visually normal peritoneum were histologically examined and 
any specimen with microscopic lesion suspected of endometriosis was re-examined and 
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confirmed by an expert histopathologist of our University (MN).  
Immunohistochemistry. The details of immunohistochemical staining were 
described elsewhere (Khan et al., 2003, 2004, 2005; Ishimaru et al., 2004). We used at 
least three slides per biopsy for immunohistochemical analysis. Briefly, five-micrometer 
thick paraffin-embedded tissues were deparaffinized in xylene and rehydrated in 
phosphate-buffered saline. After immersion in 0.3% H202/methanol to block 
endogenous peroxidase activity, sections were pre-incubated with 10% normal goat 
serum to prevent nonspecific binding and then incubated overnight at 4℃ with respective 
antibodies. The slides were subsequently incubated with biotinylated second antibody for 
10 minutes, followed by incubation with avidin-peroxidase for 10 minutes and visualized 
with diaminobenzidine. Finally, the tissue sections were counterstained with Mayer’s 
hematoxylene, dehydrated with serial alcohols, cleared in xylene, and mounted.  
 The immunoreactivities of ER/PR, aromatase cytochrome P450, TLR4, and 
CA125/MUC16 in biopsy specimens were quantified by a modified method of 
quantitative-histogram score (Q-H score) as described elsewhere (Khan et al., 2003, 
2005; Ishimaru et al., 2004). The Q-H score was calculated using the following equation: 
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Q-H score=ΣPi (i+1), where i = 1, 2 or 3 and Pi is the percentage of stained cells for each 
intensity. The staining intensity was graded as 0 = no, 1 = weak, 2 = moderate, and 3 = 
strong. We calculated the mean Q-H scores of five different fields of one section by light 
microscopy at moderate magnification (x200).  
The cell proliferation index (Ki-67 index) in each tissue section was calculated 
by measuring the mean percentage of Ki-67-positive nuclei among total cells in four 
different microscopic fields (x200) as we described before (Khan et al., 2010b). The 
lymphatic vessel and micro-vessel density, as measured by total vessel number and as 
immunoreactive to D2-40 and VWF, respectively, were counted by light microscopy of 
those areas that contained the highest number of lymphatics, capillaries and venules, as 
described elsewhere (Khan et al., 2003). The total lymphatic vessel and micro-vessel 
counts were evaluated in the same specimen.  
By the term “tissue activity” in this study, we mean the capacity of a tissue or 
OME lesion to express different molecular markers and to have variable proliferative 
potentiality in the examined tissue or lesion.      
Statistical Analysis. All results are expressed as either mean ± SD or mean ± 
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SEM. The clinical characteristics of the subjects were compared with one-way analysis of 
variance and the X2 test was used for any difference between two groups. Mann-Whitney 
U-test or Student’s t-test was used to analyze any difference in protein expressions 
between two groups. For comparisons among groups, the Kruskal-Wallis test was used. A 
box plot analysis of different protein expression was performed using the medians and 
inter-quartile range (IQR). A value of p<0.05 was considered to be statistically 
significant. 
Results 
There were no significant differences in clinical characteristics between 151 
women with visible endometriosis and 62 control women without endometriosis (Table 
1). We could collect visually normal peritoneum from these two groups of women for our 
study purpose. All OME lesions were detected at a distance of 100-800μm beneath the 
mesothelium of normal peritoneum.  
We detected three patterns of OME: (I) presence of typical gland/stroma, (II) 
reactive hyperplastic change of endometrioid epithelial cells with surrounding stroma, 
and (III) single-layered epithelium-lined cystic lesions with surrounding stromal cells. 
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We could detect variable patterns of OME in the peritoneum derived from 23 women with 
endometriosis (biopsy samples, n=27) and 4 control women (biopsy samples, n=4) 
without visible endometriosis. The detection rate of OME was as follows: for 
endometriosis, 15.2% (23/151) and 11.8% (27/227); for control women, 6.4% (4/62) and 
5.1% (4/78) by the number of patients and number of collected samples, respectively. A 
higher tendency in the incidence of OME was found in women with visible endometriosis 
than in control women (p=0.06 by patient number and p=0.07 by sample number, 
analyzed by X2 test) (Table 2). With the concept of stromal endometriosis in mind, we 
found it in only 3 cases. We did not include them as a separate pattern (pattern IV) due to 
less sample number. All these 3 cases with endometriotic stroma were immunoreactive to 
CD10 and non-reactive to either Ber-EP4 or Calretinin. 
The distribution of three patterns of OME was as follows: endometriosis, 
pattern I (n=18), pattern II (n=9), and pattern III (n=6); control women, pattern I (n=3), 
pattern II (n=0), and pattern III (n=1). A total of 33 and 4 IME lesions were detected in 
women with visible endometriosis and control women, respectively. The detection 
pattern of OME lesions based on anatomical site of peritoneum was as follows: 
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endometriosis (total sample, n=27), Pouch of Douglas (n=6), uterovesicle space (n=10), 
right sacrouterine ligament (n=5), left sacrouterine ligament (n=6); control women (total 
sample, n=4), Pouch of Douglas (n=1), uterovesicle space (n=2), right sacrouterine 
ligament (n=0), left sacrouterine ligament (n=1). A predominance of OME occurrence 
was observed in Pouch of Douglas and uterovesicle space.  
Some normal peritoneal samples displayed more than one OME lesion. 
Therefore, a total of 33 OME lesions were detected in 27 peritoneal samples in women 
with visible endometriosis. We found peritoneal pockets in the peritoneum of two cases 
that were derived from rectovaginal pouch of women with visible endometriosis but these 
two cases lacked OME lesion anywhere in the pelvis including pockets.   
The clinical profiles of patients with OME in 23 women with visible 
endometriosis and 4 control women are shown in Table 3. There was no difference in 
mean ages between them (34.4 vs. 34.2yrs). A dominant presence of r-ASRM stage I-II 
endometriosis, red/black lesions and complain of dysmenorrhea was observed in women 
with visible endometriosis harboring OME in their peritoneum.        
Immunostaining pattern of Ber-EP4/CD10/Calretinin in OME. We found 
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that glandular epithelial cells/rim-like epithelial cells and surrounding stromal cells of 
three patterns of OME lesions were immunoreactive to Ber-EP4 and CD10, respectively 
but non-reactive to Calretinin, which is a marker of mesothelial cells (Figure 2). Only 
three OME lesions of pattern II/III showed negative immunoreaction either to Ber-EP4, 
CD10 or Calretinin. Flat mesothelial cells derived from visually normal peritoneum were 
immunoreactive to Calretinin, non-reactive to CD10 and partially reactive to Ber-EP4. 
We used biopsy specimens from mesothelioma as a positive control and found that these 
cells were strongly immunoreactive to Calretinin (inset, Figure 2).  
Immunostaining pattern of ER and PR in OME. A variable pattern of ER and 
PR immunoexpressions was observed in all OME lesions detected in women with visible 
endometriosis and control women (Figure 3, A, B). The immunoreactivity of PR as 
measured by Q-H score appeared to be higher in all patterns of OME lesions detected in 
women with visible endometriosis comparing to ER expression (Figure 3, C). In contrast 
to OME lesions, ER/PR expressions did not show any apparent difference in the 
corresponding eutopic endometria of these two groups of women across the phases of the 
menstrual cycle (data not shown).    
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Immunostaining pattern of aromatase in OME. In an attempt to examine the 
possibility of local estrogen production by OME lesions, we found that all these OME 
lesions express a variable amount of aromatase P450. An apparent immunoreaction to 
aromatase was found in visible peritoneal lesions and in OME lesions derived from 
women with visible endometriosis and in control women (Supplementary Fig. 1).      
Immunostaining pattern of TLR4 in OME. As a pattern recognition receptor, 
immunoexpression of TLR4 was found in red/black lesions, in all patterns of OME 
diagnosed in women with visible endometriosis and control women (Figure 4, A-C). In 
addition to visible and occult lesions of endometriosis, TLR4 immunoreactivity was also 
found in micro-vessels as observed in different anatomical sites of peritoneum derived 
from women with and without endometriosis (Figure 4, D).            
Immunoexpression of Ki-67 in OME. In order to examine the cell proliferation 
potentiality of OME lesions, we investigated immunoexpression of Ki-67, a cell 
proliferation marker, in visible peritoneal lesions and in OME lesions (Figure 5). A strong 
immunoreaction of Ki-67 was found in red lesions and pattern I/II OME lesions in 
women with visible endometriosis. A weak Ki-67 expression was found in pattern I/III 
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OME lesions diagnosed in control women (Figure 5, A, B, C). Ki-67 index was 
significantly higher in red lesions than in black lesions (p<0.05) and in pattern I/II OME 
lesions than in pattern III OME lesions found in women with visible endometriosis 
(p<0.05 vs. pattern I or pattern II) (Figure 5, D). 
Immunostaining pattern of D2-40 and VWF in OME. As a marker of 
lymphatic vessels and vascular micro-vessels, we examined immunoreaction of D2-40 
and VWF, respectively, in serial sections derived from visually normal peritoneum. A 
variable immunoexpression of D2-40 and VWF was found in lymphatic cells and 
micro-vessels of all examined biopsies derived from women with visible endometriosis 
and in control women. Number of D2-40/VWF immunoreactve lymphatic/vascular 
channels appeared to be higher in women with endometriosis than in controls in the 
peritoneum adjacent to OME lesions. In contrast, lymphatic/vascular numbers appeared 
to be higher in controls than in women with endometriosis in the peritoneum distant from 
OME lesions. There was no significant difference in lymphatic or micro-vessel count 
between these two groups of women in either area (Supplementary Fig. 2 and Fig. 3).  
Immunostaining pattern of CA125/MUC16 in OME. A variable 
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immunoexpression of CA125/MUC16 was found in red/black lesions, pattern I/II/III 
OME lesions detected in women with visible endometriosis and in pattern I/III OME 
lesions detected in control women (Figure 6, A, B, C). It was interesting to observe that 
all three Ber-EP/CD10/Calretinin had non-reactive OME lesions (pattern II/III) were also 
immunoreactive to CA125/MUC16 (Figure 6, D). We did not find any difference in the 
immunoreactivity of CA125/MUC16 among these visible and occult lesions as measured 
by Q-H scores (data not shown). Normal peritoneal mesothelium was also found to be 
immunoreactive to CA125/MUC16 (inset, Figure 6, D). 
Discussion 
 We re-established more than a decade old concept of IME (Redwine, 1988, 
1990; Balasch et al., 1996) using increased number of visually normal peritoneal samples. 
In order to avoid confusion in the use of the term “invisible” or “non-visible” microscopic 
endometriosis among laparoscopists, here we used the term “occult” microscopic 
endometriosis (OME) instead of IME to indicate any hidden lesion in visually normal 
peritoneum. We demonstrated that occurrence of OME in visually normal peritoneum 
was higher in women with visible peritoneal endometriosis than in control women. Our 
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detection rate of OME in women with visible endometriosis (15.2%) and in control 
women (6.4%) is in consistence with the published incidence rate of 6-13% (Nisolle et 
al., 1990) and of 6-11% as reported by Balasch et al. (1996). Although rejected previously 
by Redwine (2003), we re-established the controversial debate once more that the concept 
of IME or OME indeed exists. Our findings coincide with the findings of Nisolle et al., 
(1990), Balasch et al., (1996) and Walter et al., (2001) and have further reinforced the 
concept of OME, the so called IME.  
We support the opinion of Donnez et al (2004) and oppose the proposal made 
by Redwine (2003) that OME is a rare and clinically unimportant entity. We followed 
some criteria of visually normal peritoneum and collected increased number of samples 
during a period of five years to re-confirm the previous concept of IME. Unlike previous 
studies (Donnez and Langrndonckt, 2004; Balasch et al., 1996), we confirmed our 
findings by random collection of peritoneal biopsy specimens from different anatomical 
locations and not from a single site. In fact, we found a higher incidence rate of OME in 
dependent part of pelvis and not in sacrouterine ligaments as reported previously.   
The classical histological diagnosis of endometriosis differs in point of views 
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between gynecologists and histopathologists. All clinical gynecologists accept diagnosis 
of endometriosis based on the findings of typical endometrial glands with peripheral rim 
of stromal cells. But the majority of histopathologists disagree with this definition and 
define endometriosis just by the presence of stromal cells around cells of coelomic 
epithelium such as gland cells, endometrioid epithelial cells, or mesothelial cells. Since 
this is a histopathology-based study, we defined endometriosis according to the opinion 
of an expert pathologist of our University (MN).   
Similar to the opinion of our pathologist (MN), Redwine and Yokom (1990) 
reported that any glandular structure within peritoneal tissue cannot be accepted as true 
endometriosis without the presence of stroma around glands. With this knowledge in 
mind, we classified OME lesions into three categories based on the presence of stromal 
cells in and around glandular structure (pattern I), hyperplastic endometrioid epithelial 
cells (pattern II) and single-layered epithelium-lined cystic lesions (pattern III). All these 
three patterns of OME lesions were immunoreactive to Ber-EP4/CD10 but non-reactive 
to Calretinin. The immunoreaction of Ber-EP4 in pattern II and III lesions may dictate the 
usefulness of Ber-EP4 staining in differentiating rim of epithelial cells that might be 
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confused with mesothelium-like cells by hematoxylin and eosin stain. In fact, antibody 
against Ber-EP4 has been reported to distinguish epithelia from mesothelia (Latza et al., 
1990). Only three OME lesions of pattern II/III showed negative immunoreaction either 
to Ber-EP4/CD10 or Calretinin. Lack of cellular differentiation or improper histogenesis 
of cells may explain this negative immunoreaction. But we cannot exclude the possibility 
of endosalpingiosis for these three lesions. Further in depth investigation is needed to 
clarify this issue.   
Even the laparoscopic tip differed between our study and study of Redwine and 
Nezhat, it is quite reasonable to detect OME lesions under microscope rather than sharp 
visible power of laparoscopic tip or sharp visual acuity of surgeon’s eyes. We presume 
that it is not always possible to identify an OME lesion located at 100-800μm beneath 
the mesothelium of normal peritoneum even the laparoscopic lens is in close proximity to 
the peritoneal surface. In fact, our findings clearly supported findings as depicted in 
Figure 2 of Redwine’s review article (2003). It is clear from findings of Redwine (2003) 
that with a distance of 3-4 cm from the peritoneal surface, the incidence of IME (here 
OME) ranges from 5-10% that coincides with our findings and findings of Nisolle (1990) 
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and Balasch (1996). Since our sample size was larger than that of Redwine’s study, our 
samples were more likely to contain some retroperitoneal glandular inclusions. We 
believe that further study with contact laparoscope is necessary to carefully differentiate 
normal from abnormal peritoneum and also to strengthen our current findings.  
We found a variable amount of tissue expressions of ER. PR, aromatase, and 
TLR4 in OME lesions and were detected in women with both visible endometriosis and 
control women. Although, PR expression appeared to be higher than ER expression in 
OME lesions, there was no obvious difference in the expression of steroid receptors in the 
corresponding endometria across the phases of menstrual cycle. Higher PR expression 
and lower ER expression in OME lesions could be due to the difference in the binding 
affinities of the antibodies to their respective antigens. The higher PR expression may be 
involved in proper decidual reaction and slow progression of these OME lesions once 
they are established. The immunoexpression of aromatase in all OME lesions could be 
another interesting findings. With the influence of both systemic and local estrogen, these 
OME lesions, even it is minute in size, may time-dependently increase in size to be 
recognized by histology.  
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We previously reported from our laboratory (Khan et al., 2010a) that a small 
amount of lipopolysaccharide (LPS) is available in pelvis across the phases of the 
menstrual cycle. This LPS derived from higher colony formation of Escherichia coli in 
menstrual blood (Khan et al., 2010a) may promote the growth of OME lesions after its 
binding with TLR4. In fact, we found moderate expression of TLR4 in all OME lesions. 
This growth promoting effect was clearly supported by significantly higher Ki-67 index, 
a cell proliferation marker, in pattern I and pattern II OME lesions diagnosed in women 
with endometriosis than in pattern III OME lesions or in control women. We are against 
the argument by Donnez et al., (2004) that IME (here OME) lesions are quiescent and 
they are non-active or inactive and that these lesions are clinically irrelevant. From our 
findings we can at least argue that OME lesions are indeed active and retain variable 
growth potentiality in response to cyclic estrogen and/or various inflammatory mediators 
in pelvis, even their concentration is minimal. This could be obviously responsible for the 
subsequent recurrence or occurrence of endometriotic lesions even after successful 
excision or ablation of visible peritoneal lesions by laparoscopy. From the logical point of 
view, it is difficult to trace these growing lesions on the peritoneal surface by repeated 
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surgical procedures in human. Therefore, consistency with Figure 2 of Redwine’s article 
(2003) and existence of variable biological activity of OME lesions in our study can be 
considered as something new and important in both biological and clinical science.  We 
can at least speculate from our current findings that OME lesions are not clinically 
irrelevant rather more or less clinically significant, because these subtle lesions of OME 
displayed some degree of biological activity. . 
The most alarming questions may arise now, ‘how can we decide the origin of 
OME lesions?’ or ‘Is Sampson’s theory enough to explain OME lesions?’ (Sampson, 
1927). There is no definite answer at this moment. But we argue that we can link each and 
every theory supporting the origin of visible endometriosis (Burney and Giudice, 2012) to 
the pathogenesis of OME lesions. If Sampson’s theory does not directly support the origin 
of OME lesions, it can be indirectly explained by lymphatic or hematogenous spread of 
menstrual debris and its subsequent localization within lymphatic/vascular channels deep 
into peritoneum as already proposed (Sampson, 1927; Javert, 1952; Hey-Cunningham et 
al., 2011). But our current findings did not support this phenomenon for OME. We failed 
to locate any OME lesion within lymphatic channel or vasculatures. Instead, we found an 
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increased angiogenic and lymphangiogenic response in and around OME lesions. This 
could be due to local inflammatory reaction in the pelvis of women with visible 
endometriosis or activity response of OME lesions.  
We cannot exclude the possibility of genetic factor or metaplastic 
transformation of peritoneal mesothelial cells in response to inflammation or 
environmental factors (Burney and Giudice, 2012). Despite possible origin of OME as a 
result of epithelial-mesenchymal transition/mesenchymal-epithelial transition or from 
stem cells (Gaetje et al., 1997: Sasson and Taylor, 2008; Maruyama and Yoshimura, 
2012), embryonic development (Mülleriosis) within peritoneum may be another possible 
mechanism to explain the origin of IME as described by Redwine in 1988.   
In addition to recognize müllerian tissue and epithelial ovarian cancer cells, 
CA125/MUC16 can be used as a marker to identify cells derived from coelomic 
epithelium (embryonic origin) and its derivatives. With this concept in mind, we extended 
our experiment to immunolocalize cells of embryonic origin by immunoreaction to 
CA125/MUC16 in OME lesions. CA125 is a high molecular weight mucin-type 
glycoprotein encoded by MUC16 gene. CA125/MUC16 is expressed in epithelial ovarian 
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cancer cells and in apical surface of coelomic epithelia and its derivatives such as 
endometrium, mesothelial cells lining body cavities and fallopian tube (Cheon et al., 
2009). As a marker of coelomic epithelial cells, we found immunoreaction of 
CA125/MUC16 in visible endometriosis and in all patterns of OME lesions. Three cases 
with OME lesions, had non-reactive to Ber-EP4/CD10/calritinin, were equally 
immunoreactive to CA125/MUC16. Our findings were further supported by the 
immunoreaction of CA125/MUC16 to normal peritoneal mesothelium. These findings 
may support the notion that cells of visible and occult endometriosis could be of 
embryonic origin (Mülleriosis) and CA125/MUC16 can be expressed irrespective of the 
presence of peritoneal pockets and anatomical sites of OME lesions. We speculate that the 
transformation of peritoneal mesothelial cells (metaplasia theory) or time-dependent 
activation of coelomic epithelium (induction theory) within peritoneum may explain the 
origin of OME lesions in our study.   
Although the theory of müllerianosis cannot be ignored as proposed by Batt 
(2013) as an additional factor in the origin of OME lesions from müllerian tissue 
associated with peritoneal pockets, our findings did not support this theory. Because even 
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we could detect two cases with peritoneal pockets derived from rectovaginal pouch of 
women with visible endometriosis, both of these cases lacked OME lesions anywhere in 
the pelvis, including peritoneal pockets.  . 
Finally, we conclude that existence of OME, previously described as IME, in 
visually normal peritoneum is true and acceptable. We rule out the previous argument and 
confirmed here by serial experiments that OME lesions are indeed biologically active and 
retain their growing potentiality. This may be involved in the persistence and/or 
recurrence of pain, recurrence of endometriosis after successful surgery or possible 
development of time-dependent overt endometriosis. Further studies are needed to 
strengthen our current findings.  
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Figure 1. Photographs of visually normal peritoneum observed during 
laparoscopy (Stortz, Germany) and were taken from the area of Pouch of Douglas (A) and 
uterovesical space (B). The criteria of visually normal peritoneum are described in 
materials and methods.  
Figure 2. Microscopically detected three patterns of occult microscopic 
endometriosis in visually normal peritoneum. Pattern I shows presence of typical 
gland/stroma; pattern II shows reactive hyperplastic change of endometrioid epithelial 
cells with surrounding stroma; and pattern III shows single-layered epithelium-lined 
cystic lesions with surrounding stromal cells (all in HE stain, upper column). The 
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identification of glandular epithelial cells, stromal cells and peritoneal mesothelial cells 
was confirmed by the immunoreaction to Ber-EP4, CD10 and Calretinin, respectively 
and are shown against each HE stained slides. Flat mesothelial cells derived from normal 
peritoneum and mesothelioma cells as a positive control (inset) immunoreactive to 
Calretinin are shown at the right panel. The immunoreactions to non-immune mouse IgG 
as a negative control are shown on the extreme right panel. HE stain, hematoxylin and 
eosin stain. Magnification of slides (x200).   
Figure 3. Immunohistochemical staining of estrogen receptor (ER, upper 
column) and progesterone receptor (PR, middle column) in different patterns of occult 
microscopic endometriosis (OME) detected in women with visible endometriosis (A) and 
in control women (B). The immunoreactions to non-immune mouse IgG as a negative 
control are shown in the lower panel of A and B. Quantitative histogram (Q-H) scores 
indicated that comparing to ER expression (white bar), immunoexpressions of PR 
(hatching bar) appeared to be higher in all patterns of OME lesions detected in women 
with endometriosis (C). Boxes represent the distance (interquartile range) between the 
first (25%) and third (75%) quartiles, and horizontal lines in the boxes represent median 
Khan KN et al., Page 38
values. Magnification of A and B (x200 and x400). 
Supplementary Figure 1. Hematoxylin and eosin stain (upper column), 
immunohistochemical staining of aromatase cytochrome P450 (middle column), and 
non-immune mouse IgG-stained negative control (lower column) in visible peritoneal 
endometriosis (red lesion), in patterns I and III lesions of occult microscopic 
endometriosis (OME) detected in women with visible endometriosis, and in control 
women. A variable amount of aromatase immunoexpression was found in patterns I/III 
OME lesions and also in red lesions.  
Figure 4. Hematoxylin and eosin stain (upper column) and 
immunohistochemical staining of Toll-like receptor 4 (TLR4, lower column) in 
peritoneal endometriosis (A), different patterns of occult microscopic endometriosis 
(OME) detected in women with visible endometriosis (B) and in control women (C). 
TLR4 immunoreaction was also observed in micro-vessels of normal peritoneum derived 
from pouch of Douglas (D, upper column) and uterovesicle space (D, lower column) of 
women with endometriosis and control women. Magnification of A, B, C, D (x200).      
     Figure 5. Hematoxylin and eosin stain (upper column) and 
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immunohistochemical staining of Ki-67 (lower column), a cell proliferation marker, in 
lesions derived from visible peritoneal endometriosis (A), different patterns of occult 
microscopic endometriosis (OME) detected in women with endometriosis (B), and in 
control women (C). The Ki-67 index (percentage of Ki-67 immunoreactive cells among 
total cells) in the respective lesions are shown in the lower right panel (D). Ki-67 index 
was significantly higher in red lesions (white bar) than in black lesions (hatching bar, 
*p<0.05). Ki-67 index was also significantly higher in patterns I or II OME lesions 
(white/hatching bar) than in pattern III lesions (gray bar, p<0.05 for each) detected in 
women with visible endometriosis. Boxes represent the distance (interquartile range) 
between the first (25%) and third (75%) quartiles, and horizontal lines in the boxes 
represent median values. Magnification of A, B, and C (x200).      
Supplementary Figure 2. Hematoxylin and eosin stain (far left column) and 
immunohistochemical staining of D2-40, a lymphatic vessel marker, in occult 
microscopic endometriosis (OME) detected in women with endometriosis (A, upper 
column) and in OME lesions of control women (A, lower column). Analysis of total 
lymphatic vessel count indicated that number of D2-40 immunoreactve lymphatic vessels 
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appeared to be higher in women with endometriosis than in controls in the peritoneum 
adjacent to OME lesions. In contrast, lymphatic vessel numbers appeared to be higher in 
controls than in women with endometriosis in the peritoneum distant from OME lesions. 
There was no significant difference in lymphatic vessel count between these two groups 
of women in either area (B). No OME lesions were found within lymphatic channels. 
Boxes represent the distance (interquartile range) between the first (25%) and third (75%) 
quartiles, and horizontal lines in the boxes represent median values. Magnification of A 
(x200).      
   Supplementary Figure 3. Hematoxylin and eosin stain (far left column) and 
immunohistochemical staining of von Willebrand factor (VWF), a micro-vessel marker, 
in occult microscopic endometriosis (OME) detected in women with endometriosis (A, 
upper column) and in OME lesions of control women (A, lower column). Analysis of 
micro-vessel density indicated that number of VWF immunoreactve micro-vessels 
appeared to be higher in women with endometriosis than in controls in the peritoneum 
adjacent to OME lesions. In contrast, micro-vessel densities (MVD) appeared to be 
higher in controls than in women with endometriosis in the peritoneum distant from OME 
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lesions. There was no significant difference in MVD between these two groups of women 
in either area (B).  No OME lesions were found within vascular channels. Boxes represent 
the distance (interquartile range) between the first (25%) and third (75%) quartiles, and 
horizontal lines in the boxes represent median values. Magnification of A (x200).      
Figure 6. Hematoxylin and eosin stain (upper column) and 
immunohistochemical staining of CA125/MUC16, a marker of cells derived from 
coelomic epithelium,  (lower column) in visible peritoneal endometriosis (red/black 
lesions, A), different patterns of occult microscopic endometriosis (OME) detected in 
women with visible endometriosis (B) and in control women (C). Pattern II and III OME 
lesions that were non-reactive to Ber-EP4/CD10/Calretinin were also immunoreactive to 
CA125/MUC16 (D). Normal peritoneal mesothelium appeared to be immunoreactive to 















Table 1. Clinical profiles of enrolled patients with and without endometriosis  
                                                        control (n=62)                      endometriosis (n=151)  
 
age in years: (mean ± SD)                 33.9 ± 7.4                                    35.1 ± 6.9           
 
range of age: (years)                             19-48                                           23-50 
 
menstrual cycle: P/S/M/A (n)            13/40/6/3                                   29/68/16/38   
 
r-ASRM staging: I/II/III/IV (n)            none                                        83/30/14/24  
 
distribution of peritoneal lesions:               
red/black/white/mixed (n)                    none                                         16/94/7/34 
 
complaint of dysmenorrhea: 
present/absent (n)                                  9/53                                             93/58 
 
GnRHa treatment before surgery: 
yes/no (n)                                              none                                            38/113 
 
coexisting diseases:             
adenomyosis/myoma (n)                        1/4                                               5/24 
 
The results are expressed as mean ± SD. r-ASRM, revised classification of the American 
Society of Reproductive Medicine; P, proliferative phase; S, secretory phase; M, 






Table 2. Detection rate of OME based on number of patients and biopsy samples  
                                     control (n=62/78)        endometriosis (n=151/227)         p value 
                                 (No. patients/samples)         (No. patients/samples) 
 
OME based on  
No. patients                     6.4% (4/62)                       15.2% (23/151)                     0.06          
 
OME based on  
No. biopsy samples         5.1% (4/78)                       11.8% (27/227)                     0.07          
 







Table 3. Clinical profiles of patients with occult microscopic endometriosis  
                                                        control (n=4)                      endometriosis (n=23)  
 
age in years: (mean ± SD)                 34.2 ± 9.7                                  34.4 ± 6.3           
 
range of age: (years)                             24-44                                          23-45 
 
menstrual cycle: P/S/M/A (n)              1/3/0/0                                       5/12/3/3   
 
r-ASRM staging: I/II/III/IV (n)             none                                         14/2/2/5  
 
distribution of peritoneal lesions:               
red/black/white/mixed (n)                     none                                         5/14/1/3 
 
complaint of dysmenorrhea: 
present/absent (n)                                    0/4                                            16/7 
 
GnRHa treatment before surgery: 
yes/no (n)                                               none                                           3/20 
 
coexisting diseases:             
adenomyosis/myoma (n)                        none                                           0/3 
 
The results are expressed as mean ± SD. r-ASRM, revised classification of the American 
Society of Reproductive Medicine; P, proliferative phase; S, secretory phase; M, 
menstrual phase; A, amenorrhea; GnRHa, gonadotropin releasing hormone agonist.            
 
 
 
 
 
 
